Published in Nephron Clin Pract on June 16, 2009
Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol (2012) 1.02
Protective effects of PPARγ agonist in acute nephrotic syndrome. Nephrol Dial Transplant (2011) 0.88
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol (2012) 0.82
Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action. Br J Pharmacol (2012) 0.80
Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. PLoS One (2015) 0.77
Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity. Am J Physiol Renal Physiol (2011) 0.77
Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats. J Biomed Res (2011) 0.77
Rosiglitazone protects against severe hemorrhagic shock-induced organ damage in rats. Med Sci Monit (2011) 0.77
Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci U S A (2009) 1.84
Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J Biol Chem (2002) 1.56
Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet (2003) 1.47
Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease. Transplantation (2015) 1.44
Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Hum Mol Genet (2007) 1.36
Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. Hum Mol Genet (2006) 1.36
Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant (2006) 1.33
Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol (2003) 1.26
A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J (2010) 1.18
Identification and functional characterization of an N-terminal oligomerization domain for polycystin-2. J Biol Chem (2008) 1.11
Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 1.10
Activation of TRPP2 through mDia1-dependent voltage gating. EMBO J (2008) 1.06
Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol (2007) 1.04
Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. J Cell Sci (2009) 1.02
Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. J Biol Chem (2004) 1.00
Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract (2011) 1.00
Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Hum Mol Genet (2013) 0.94
Protein kinase D-mediated phosphorylation of polycystin-2 (TRPP2) is essential for its effects on cell growth and calcium channel activity. Mol Biol Cell (2010) 0.93
A single amino acid residue constitutes the third dimerization domain essential for the assembly and function of the tetrameric polycystin-2 (TRPP2) channel. J Biol Chem (2011) 0.91
Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation (2007) 0.90
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
Polycystin-2 expression is increased following experimental ischaemic renal injury. Nephrol Dial Transplant (2002) 0.83
Endothelin in polycystic kidney disease. Contrib Nephrol (2011) 0.82
Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol (2012) 0.82
The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease. PLoS One (2013) 0.82
Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA. Nephron Clin Pract (2013) 0.82
Screening for intracranial aneurysms in ADPKD. BMJ (2009) 0.78
Fabrication and luminescence of monolayered boron nitride quantum dots. Small (2013) 0.78
Fabrication of luminescent monolayered tungsten dichalcogenides quantum dots with giant spin-valley coupling. ACS Nano (2013) 0.78
Autosomal dominant polycystic kidney disease. Clin Med (2009) 0.78
Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity. Am J Physiol Renal Physiol (2011) 0.77
The ERA-EDTA Working Group on inherited kidney disorders. Nephrol Dial Transplant (2012) 0.76
Cystic kidney diseases: many ways to form a cyst. Pediatr Nephrol (2012) 0.76
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch (2013) 0.75
Erratum. Nephrol Dial Transplant (2017) 0.75